BeiGene Ltd ADR (NASDAQ: BGNE)’s stock price has gone decline by -7.74 in comparison to its previous close of 211.15, however, the company has experienced a 1.68% increase in its stock price over the last five trading days. businesswire.com reported 2024-09-09 that STÄFA, Switzerland & VALENCIA, Calif.–(BUSINESS WIRE)– #cochlear–Phonak, a leading provider of life-changing hearing solutions, and its sister brand and partner Advanced Bionics (AB), a global leader in cochlear implant technology, proudly sponsor Rally Caps. This heartwarming family film highlights the power of team building, friendship, and breaking down stigmas associated with hearing loss. Written for the screen and directed by Lee Cipolla, Rally Caps is a moving coming-of-age film adapted from the.
Is It Worth Investing in BeiGene Ltd ADR (NASDAQ: BGNE) Right Now?
BGNE has 36-month beta value of 0.60. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BGNE is 96.27M, and currently, short sellers hold a 2.34% ratio of that float. The average trading volume of BGNE on September 12, 2024 was 276.24K shares.
BGNE’s Market Performance
The stock of BeiGene Ltd ADR (BGNE) has seen a 1.68% increase in the past week, with a 4.06% rise in the past month, and a 15.88% gain in the past quarter. The volatility ratio for the week is 3.01%, and the volatility levels for the past 30 days are at 2.46% for BGNE. The simple moving average for the past 20 days is -0.05% for BGNE’s stock, with a 18.36% simple moving average for the past 200 days.
Analysts’ Opinion of BGNE
Many brokerage firms have already submitted their reports for BGNE stocks, with JP Morgan repeating the rating for BGNE by listing it as a “Overweight.” The predicted price for BGNE in the upcoming period, according to JP Morgan is $185 based on the research report published on February 06, 2024 of the current year 2024.
Macquarie, on the other hand, stated in their research note that they expect to see BGNE reach a price target of $259. The rating they have provided for BGNE stocks is “Outperform” according to the report published on September 12th, 2023.
Jefferies gave a rating of “Buy” to BGNE, setting the target price at $287 in the report published on August 17th of the previous year.
BGNE Trading at 11.82% from the 50-Day Moving Average
After a stumble in the market that brought BGNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.39% of loss for the given period.
Volatility was left at 2.46%, however, over the last 30 days, the volatility rate increased by 3.01%, as shares surge +4.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +35.20% upper at present.
During the last 5 trading sessions, BGNE rose by +1.58%, which changed the moving average for the period of 200-days by +5.35% in comparison to the 20-day moving average, which settled at $195.30. In addition, BeiGene Ltd ADR saw 8.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BGNE starting from Wu Xiaobin, who sale 5,556 shares at the price of $189.65 back on Sep 03 ’24. After this action, Wu Xiaobin now owns 0 shares of BeiGene Ltd ADR, valued at $1,053,677 using the latest closing price.
Ball Titus B., the Principal Accounting Officer of BeiGene Ltd ADR, sale 137 shares at $189.94 during a trade that took place back on Sep 03 ’24, which means that Ball Titus B. is holding 0 shares at $26,022 based on the most recent closing price.
Stock Fundamentals for BGNE
Current profitability levels for the company are sitting at:
- -0.29 for the present operating margin
- 0.83 for the gross margin
The net margin for BeiGene Ltd ADR stands at -0.17. The total capital return value is set at -0.23. Equity return is now at value -14.62, with -9.15 for asset returns.
Based on BeiGene Ltd ADR (BGNE), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -0.67. The debt to equity ratio resting at 0.31. The interest coverage ratio of the stock is -32.66.
Currently, EBITDA for the company is -1.12 billion with net debt to EBITDA at 1.82. When we switch over and look at the enterprise to sales, we see a ratio of 6.81. The receivables turnover for the company is 5.26for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.98.
Conclusion
To put it simply, BeiGene Ltd ADR (BGNE) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
